Several factors limit PD-L1 expression as a biomarker for colon cancer immunotherapy response: First, there is intratumoral heterogeneity of PD-L1 expression (135), which makes assessing tumor PD-L1 expression level. This evidence concerns the gene CD274 and neoplasm.